1. Home
  2. ACRS vs SKYH Comparison

ACRS vs SKYH Comparison

Compare ACRS & SKYH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$4.34

Market Cap

311.0M

Sector

Health Care

ML Signal

HOLD

Logo Sky Harbour Group Corporation

SKYH

Sky Harbour Group Corporation

HOLD

Current Price

$9.18

Market Cap

321.0M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACRS
SKYH
Founded
2012
2017
Country
United States
United States
Employees
N/A
112
Industry
Biotechnology: Pharmaceutical Preparations
Military/Government/Technical
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
311.0M
321.0M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
ACRS
SKYH
Price
$4.34
$9.18
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
4
Target Price
$10.20
$13.13
AVG Volume (30 Days)
1.1M
175.4K
Earning Date
05-07-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
69.01
N/A
EPS
N/A
N/A
Revenue
$1,683,000.00
N/A
Revenue This Year
N/A
$78.89
Revenue Next Year
$4.24
$73.15
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.34
$8.22
52 Week High
$5.15
$11.17

Technical Indicators

Market Signals
Indicator
ACRS
SKYH
Relative Strength Index (RSI) 47.71 45.58
Support Level $4.15 $8.92
Resistance Level $4.73 $9.67
Average True Range (ATR) 0.24 0.31
MACD -0.04 0.04
Stochastic Oscillator 39.64 39.06

Price Performance

Historical Comparison
ACRS
SKYH

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

About SKYH Sky Harbour Group Corporation

Sky Harbour Group Corp is an aviation infrastructure company focused on building the first nationwide network of Home Base Operator (HBO) campuses designed exclusively for business aircraft. The company develops, leases, and manages general aviation hangars across the United States, targeting airfields in markets with aircraft populations and high hangar demand. Its HBS campuses include private hangars and offer a range of services tailored to aircraft owners operating from these facilities. The majority of the company's revenue is derived from the leasing of home-based aircraft hangars and through services and products ancillary to its leasing activities.

Share on Social Networks: